Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco ... has recently been initiated (outside of the US). The open-label, first-in-human, dose escalation study will ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

WHIPPANY, NJ, USA I January 14, 2025 I On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with ...

WHIPPANY, N.J.--(BUSINESS WIRE)--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco ... has recently been initiated (outside of the US). The open-label, first-in-human, ...

Bayer has joined its peers among European drugmakers ... while simultaneously addressing the longer-term roadblocks holding us back," he remarked. "The 154 days since March 5th have been pretty ...